Resources in German

More
novel drugs –
Inspiring
potential

As a biopharmaceutical company headquartered in Allschwil/Basel, Switzerland, we have many people interested in reading more about the company in German.

Als schweizerisches Unternehmen stellen wir interessierten Personen auf dieser Seite wesentliche Informationen über unser Unternehmen in deutscher Sprache zur Verfügung.

Medieninformationen

Idorsia bietet ausgewählte Medienmitteilungen und Informationsmaterial auch in deutscher Sprache an.

Latest news

23 May 2022

Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension

10 May 2022

Phase 2a study results in binge eating disorder

03 May 2022

Europe’s first dual orexin receptor antagonist – QUVIVIQ (daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder

02 May 2022

Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia

26 Apr 2022

Idorsia gibt Finanzergebnisse für das erste Quartal 2022 bekannt – Erstes Produkt eingeführt, zweites Produkt in den Startlöchern

20 Apr 2022

PIVLAZ (clazosentan) – Idorsia’s first commercial product – now available for patients in Japan

14 Apr 2022

Idorsia hält ordentliche Generalversammlung ab

04 Apr 2022

The Journal of Neurosurgery reports impact of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage

10 Mar 2022

New data for daridorexant in patients with insomnia disorder – including long-term safety and efficacy – to be presented at World Sleep 2022

03 Mar 2022

Idorsia veröffentlicht Ankündigung der ordentlichen Generalversammlung 2022

25 Feb 2022

QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder

08 Feb 2022

Idorsia gibt Finanzergebnisse für 2021 bekannt – 2022 wird ein Jahr der Transformation – Nachhaltige Rentabilität soll 2025 erreicht werden

26 Jan 2022

Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada

24 Jan 2022

Idorsia ernennt Guy Braunstein zum Chief Medical Officer und Alberto Gimona zum Head of Global Clinical Development

20 Jan 2022

Idorsia receives Japanese PMDA approval of PIVLAZ (clazosentan sodium) 150 mg

20 Jan 2022

The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia

12 Jan 2022

Jennifer Aniston partners with Idorsia U.S. to launch ‘Seize the Night & Day’ campaign inspiring Americans to understand their relationship with sleep

10 Jan 2022

Idorsia presents at the 40th J.P. Morgan Healthcare Conference – Ready for first product launches – QUVIVIQ (daridorexant) approved by the US FDA

10 Jan 2022

Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia

13 Dec 2021

Idorsia to further characterize lucerastat for the treatment of Fabry disease by continuing the open-label extension of the Phase 3 MODIFY study

Ad hoc announcements pursuant to Art. 53 LR

Ad hoc announcements pursuant to Art. 53 LR have been classified from 2021 onwards. A full archive of press releases can be found under the "All" tab.

"I enjoy working for Idorsia because it is exciting to take part and contribute to success."
Senior Research Associate, Chemistry

Resources in German

More novel drugs – Inspiringpotential

Latest news

Share this page:

Ad hoc announcements pursuant to Art. 53 LR

Related Content

More
novel drugs –
Inspiring
potential